Wilson Marc's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Jun 21, 2023
- Accession no.
- 0001209191-23-038852
- Filed
- Jun 21, 2023
- Trade date
- Jun 20, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $617.4K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wilson MarcCIK 0001702265 | Officer (CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2023 | Common Stock | SSaleDisposed | −10,922 | $19.96F1 | −$218,003.12 | 95,158 | Direct | |
| Jun 20, 2023 | Common Stock | MOption exerciseAcquired | +20,000 | $9.28 | +$185,600 | 115,158 | Direct | |
| Jun 20, 2023 | Common Stock | SSaleDisposed | −20,000 | $19.97F2 | −$399,400 | 95,158 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 20, 2023 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 71,185 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $19.96 per share. The range of sales prices on the transaction date was $19.86 to $20.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F2
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $19.97 per share. The range of sales prices on the transaction date was $19.86 to $20.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.